Although 76% respondents reported encountering medical misinformation, that exposure was not significantly associated with clinically significant fear of cancer recurrence or self-reported treatment ...

Gathering first-degree family histories for patients with childhood cancers through currently available questions and a personal history is sufficient to ...

Investigators evaluated the efficacy and safety of toripalimab versus dacarbazine as the first-line treatment in advanced melanoma predominantly of acral subtype.

In this analysis, researchers aimed to evaluate the clinicopathologic characteristics, metastatic patterns, and survival outcomes in patients with metastatic prostate cancer and low-volume primary ...

In May, the U.S. Food and Drug Administration (FDA) approved the first at-home cervical cancer screening tool, developed by Teal Health. The wand allows patients to collect a vaginal sample themselves ...

(HealthDay News) — Email communications can increase clinician engagement with prescription drug monitoring programs (PDMPs), according to a study published online Dec 19 in JAMA Health Forum.

Zanidatamab plus chemotherapy delays progression or death in patients with untreated locally advanced or metastatic gastroesophageal adenocarcinoma.

Investigators evaluated the benefit of leuprorelin immediately after radical prostatectomy for prostate cancer in patients with undetectable PSA levels.

The American Cancer Society’s Report on the Status of Cancer Disparities in the United States examines disparities in cancer occurrence and outcomes, and analyzes the factors that contribute to these ...

The Food and Drug Administration (FDA) has approved Rybrevant Faspro™, a subcutaneous (SC) formulation of amivantamab for all indications approved for the ...

In this study, researchers aimed to characterize cardiometabolic risk factors and cardiovascular disease incidence in racially and ethnically underrepresented women with breast cancer.

Investigators explored the association between baseline patient-reported fatigue and the risk adverse events in cancer treatment trials.